Medical Imaging Markets: Contrast Agents

Medical Imaging Markets: Contrast Agents
Today's capabilities in clinical diagnostic radiology have been made possible by advances not
only in diagnostic systems, but also by the contrast media and radiopharmaceuticals that make it
possible to see, in great detail, the body's internal structures, organs and tissue that would
nototherwise be clearly seen. Although bones are readily apparent on radiographic images, other
organs and tissues are not. These imaging agents may be usedduring a medical imaging
procedure to highlight specific parts of the body andmake them easier to visualize. The
application and versatility of medical imaging modalities are continuing to grow in significance
as the population ages and healthcare costs rise. Examinations that can facilitate earlier disease
diagnosis and the most appropriate treatment are in order. This bodes well for contrast media
markets.

Generally, the market for contrast agents and radiopharmaceuticals is expected to sustain decent
growth in the next fewyears, with much of that growth coming from the MRI, ultrasound and
nuclear medicine modalities. While equipment manufacturers may have experienced a slumpin
sales due to the recent recession, there is still a need for these agents,as well as for
radiopharmaceuticals, to help image, track and diagnose disease, especially in the elderly. Even
though hospitals and clinics may have slowed their equipment purchases because of the need to
contain costs, procedures run on installed systems still require the use of contrast agents and
radiopharmaceuticals.

This comprehensive study of the world market for contrast agents builds on the previous
modality-focused reports of Kalorama's medical imaging market reports. Coverage includes:
World and regional revenue forecasts for contrast agents and radiopharmaceuticals by
modality through 2016. (X-Ray, CT, Ultrasound, MRI, PET, SPECT)
Market share of the major contrast agent supplers
Procedure volumes by modality and region
Estimates of the portion of procedures in each modality using contrast enhancement
Contrast-enhancement products in development
The report also discusses technical developments and emerging application trends such as
therapeutic monitoring, whole body screening, and guided therapeutic interventions, and how
contrast agents are helping to expand imaging's role in basic research and drug
discovery/development. Specific advances in contrast agent-enabled diagnostics for
mammography, Alzheimer's, and other indications are also reviewed.

The report concludes with profiles of top suppliers and developers including:
Acusphere Inc.
Alseres Pharmaceuticals Inc.
Amag Pharmaceuticals Inc.

---

Aposense Ltd.
Avid Radiopharmaceuticals Inc.
Bayer Schering Pharma
Bracco SpA
Cell Point
Covidien Ltd.
Daiichi Pharmaceutical Co. Ltd.
Dendritic NanoTechnologies Inc.
Draximage
Endocyte Inc.
Eusa Pharma
GE Healthcare
Guerbet Group
Hovione FarmaCiencia SA
Imcor Pharmaceutical Co.
Immunomedics Inc.
Insight Agents GmbH
King Pharmaceuticals Inc.
Luna nanoWorks
Macrocyclics
MDS Nordion
NanoScan Imaging
Palatin Technologies Inc.
Pharmacyclics
Point Biomedical Corp.
Starpharma Holdings Ltd.
VisEn Medical Inc.
Buy your copy of this report @ http://www.reportsnreports.com/reports/260-medical-imaging-
markets-contrast-agents.html
Report Details:
Published: July 2012
No. of Pages: 145
Price : Single User License: US$ 3995 Price : Corporate User License: US$ 7990




Table of contents

HAPTER ONE: Executive Summary

Image Enhancament Overview
X-Ray and CT

---

Ultrasound
MRI
Radiopharmaceuticals
World Market Summary
Volume Growth
New Diagnostics
Toxicity Issues
Generic Competition
World Market Growth Analysis
Methodology

CHAPTER TWO: Introduction

Agents for the Early Detection of Disease
Two Functions
Adding Value
Key Clinical Markets
X-Ray and CT
Ultrasound
Updated Warning on Microbubbles
Microbubble Composition
Targeted and Untargeted
MRI
Novel Agents
Nuclear Medicine
Diagnosing Functionality
Sourcing Issues Updated
PET
New Applications
SPECT
Gamma Cameras
Risks
Ionic and Non-Ionic Contrast
Issues
Utilization Rate
Technical Challenges
Tracking Contrast Media
Contrast Modality Combinations
Emerging Applications
Atherosclerosis
Nanotechnology

CHAPTER THREE: Market Developments

Market Developments
FDA Approves Amyvid

---

Bayer HealthCare Business Integration
Bayer Receives Gadavist Approval
Agfa's Generic Push
Agfa's Generic Push
Improving Magnetic Resonance Visualization
Nanoparticle Contrast
Tracking Stem Cells

CHAPTER FOUR: Markets

Market Drivers
Withstanding the Recession
Combination Imaging and Disease Management
Opportunities from Increasing Specificity
Aging Population
Utilization
Procedures
Outlook for Contrast Media
Market Forecast
X-Ray and CT
Ultrasound
MRI
Outlook for Molecular Imaging Agents
Market Forecast

CHAPTER FIVE: Corporate Profiles

Acusphere Inc..
Alseres Pharmaceuticals, Inc.
Amag Pharmaceuticals Inc
Aposense Ltd
ART Advanced Research Technologies Inc.
Avid Radiopharmaceuticals Inc
Bayer HealthCare
Bracco SpA
Cardinal Health
Cell>Point
Covidien plc
Daiichi Pharmaceutucal Co. Ltd
Draximage
Endocyte Inc
Eusa Pharma
FluoroPharma Medical Inc
GE Healthcare
Guerbet Group
Hovione Farmaciencia SA

---

Immunomedics Inc
Insight Agents
Kereos Inc
King Pharmaceuticals
Lantheus Medical Imaging
Luna Nanoworks
Macrocyclics
MDS Nordion
Molecular Insight Pharmaceuticals, Inc
Nanoscan Imaginf LLC
Palatin Technologies Inc
Pharmacyclics
Spago Imaging AB
Targeson Inc
Taejoon Pharmaceutical Co. Ltd
VisEn Medical
Zim Laboratories India Ltd

Contact: sales@reportsandreports.com for further details.

---